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delivery is necessary and needs to be taken into account 
according to the specificity of their delivery to tumors and/
or normal tissues. Based on the current knowledge, electro-
chemotherapy (a combination of drug and electric pulses) 
is used for tumor treatment and has shown great potential. 
Its local effectiveness is up to 80 % of local tumor con-
trol, however, without noticeable effect on metastases. In 
an attempt to increase systemic antitumor effectiveness of 
electrochemotherapy, electrotransfer of genes with immu-
nomodulatory effect (immunogene electrotransfer) could 
be used as adjuvant treatment. Since electrochemotherapy 
can induce immunogenic cell death, adjuvant immuno-
gene electrotransfer to peritumoral tissue could lead to 
locoregional effect as well as the abscopal effect on distant 
untreated metastases. Therefore, we propose a combination 
of electrochemotherapy with peritumoral IL-12 electro-
transfer, as a proof of principle, using electrochemotherapy 
boosted with immunogene electrotransfer as in situ vacci-
nation for successful tumor treatment.
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Abbreviations
ATP  Adenosine triphosphate
B7-1  B7 protein
CTL  Cytotoxic T cells
DAMP  Danger-associated molecular pattern molecules
DC  Dendritic cells
E  Electric field
GM-CSF  Granulocyte-macrophage colony-stimulating 
factor
GTP  Guanosine triphosphate
hTERT  Human telomerase reverse transcriptase
IL-12  Interleukin 12
Abstract Electroporation is a platform technology for 
drug and gene delivery. When applied to cell in vitro or tis-
sues in vivo, it leads to an increase in membrane perme-
ability for molecules which otherwise cannot enter the cell 
(e.g., siRNA, plasmid DNA, and some chemotherapeutic 
drugs). The therapeutic effectiveness of delivered chemo-
therapeutics or nucleic acids depends greatly on their suc-
cessful and efficient delivery to the target tissue. Therefore, 
the understanding of different principles of drug and gene 
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IL-2  Interleukin 2
PDGF-α  Platelet-derived growth factor
pDNA  Plasmid DNA
ROS  Reactive oxygen species
siRNA  Small interfering RNA
TAA  Tumor-associated antigens
TLS  Tertiary lymphoid structures
TNF-α  Tumor necrosis factor alpha
Treg  T regulatory cells
Uc  Critical voltage
Um  Transmembrane voltage
VEGF  Vascular endothelial growth factor
Background
It is known that malignant tumors are able to grow and 
spread because of their ability to escape the immune sys-
tem surveillance. In fact, there is a process called “can-
cer immunoediting” that recognizes the existence of a 
fine interaction between the immune system and tumors, 
indicating the dual role the immunity plays in cancer [1]. 
Namely, the immune system not only protects the host 
against tumor growth, but can promote cancer development 
by selection of tumor variants with reduced immunogenic-
ity [2]. One promising approach to treat cancer is so-called 
active immunotherapy, aiming to induce an endogenous 
tumor-specific immune response in the host. Immuno-
therapy strategies can include cancer vaccines based on 
plasmid DNA (pDNA) vectors used to deliver tumor anti-
gens and/or immunomodulatory molecules to stimulate the 
immune system or oligonucleotides acting on immunosup-
pressor genes. Current data also support the idea that it is 
possible to strengthen the anticancer immune response by 
eliminating or inhibiting the immunosuppressive regulatory 
T cells (Treg) and by blocking the immune checkpoints 
[3–5].
In the treatment of tumors, several local therapeutic 
options are available, from surgery and radiotherapy as 
prevalent, to thermal ablation techniques, like radiofre-
quency ablation and cryosurgery, to electrochemotherapy, 
which is currently being recognized throughout Europe. 
The effectiveness and safety have brought electrochemo-
therapy into guidelines for the treatment of different cuta-
neous and subcutaneous tumors [6]. Recent meta-analysis 
has evaluated the effectiveness of several ablative skin-
directed therapies and clearly indicated the same, or even 
superior, effectiveness of electrochemotherapy over pho-
todynamic therapy, radiotherapy, intralesional therapy, and 
topical therapy [7]. Many of these local treatments, like 
thermal ablation techniques, have different modes of tumor 
cell death that can elicit different local immune response, 
which is not sufficient to elicit also strong systemic effect. 
However, these local treatments could be combined with 
immune adjuvants that would stimulate a more robust anti-
tumor action and hopefully elicit also a systemic immune 
response [8]. For some of these local treatments, the elic-
ited immune response resulted in a systemic effect, in so-
called abscopal response on distant, nontreated nodules. 
Such cases were described after radiotherapy [9]. In light 
of these effects, novel approaches may, when appropri-
ately designed, take advantage of the elicited local immune 
response and transform it into the systemic response. Elec-
trochemotherapy, a combination of chemotherapy and elec-
troporation, offers itself as another candidate.
In addition to electrochemotherapy, another biomedical 
application that is based on electroporation is gene electro-
transfer, which even though still in early clinical develop-
ments has already entered several clinical trials [10]. In the 
clinical trial with plasmid coding for interleukin 12 (IL-12) 
electro transferred to some melanoma nodules, the local 
as well as the loco regional effect on nontreated nodules 
was observed [11]. Thus, gene electrotransfer of various 
immunomodulatory molecules could be used for the immu-
nomodulation of the host’s response. In this respect, local 
ablative effect of electrochemotherapy may set the stage 
for the enhanced systemic immune response that is elicited 
by delivery of the therapeutic gene into the organism with 
immunomodulatory activity.
When using electroporation as a platform technology 
for drug and gene delivery, electrical parameters must be 
adjusted for delivery of different molecules and for differ-
ent target tissues [12, 13]. Electrical parameters that need 
to be considered are of temporal and spatial nature. Electric 
pulses that are delivered are of certain duration, shape and 
amplitude, which characterize their temporal nature. Elec-
tric pulses are delivered to cells/tissue via electrodes which, 
by their shape and positioning, together with the tissue ana-
tomical features and electrical passive properties determine 
spatial distribution of current density and electric field, and 
this is to be considered of spatial nature. The community 
that intends to use this technology needs to be aware of the 
principles of electroporation effects at the cellular and tis-
sue level based on temporal and spatial consideration, with 
respect to the specific molecules to be introduced.
Based on the assumption that local treatments can elicit 
immune response, which can be boosted by gene elec-
trotransfer of immunomodulatory molecules, we need 
to develop strategies to combine local tumor treatments, 
such as electrochemotherapy with gene electrotransfer 
that will be tailored to specific tumor, tissue, and specific 
mode of action of the therapeutic molecule. In line with 
this, we describe here, principles of electroporation on cel-
lular and tissue levels. We also propose a strategy, where 
electrochemotherapy-treated tumor could be used as a live 
vaccine in conjunction with gene electrotransfer to tumors 
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(intratumorally or peritumorally) boosting local immune 
response to tumor together with “abscopal effect” on dis-
tant metastases.
Cell electroporation can be controlled
The knowledge of the theoretical background of electropo-
ration is crucial to obtain the most suitable protocol for 
drug and/or gene delivery [14]. Two key phenomena are 
induced in the cell membrane: (1) the induced transmem-
brane voltage, which is crucial for achieving increased 
membrane permeability, and (2) the transport of the mole-
cules through the permeabilized cell membrane during and 
after the electric pulse application.
When a cell is exposed to an external electric field E, 
a transmembrane voltage Um is induced across the plasma 
membrane due to the difference between the electric 
properties of cell membrane, the cytoplasm, and external 
medium. The induced transmembrane voltage on a spheri-
cal cell for a constant electric pulse can be derived from the 
Laplace equation, which gives a time-dependent solution 
for the induced transmembrane voltage on a cell membrane 
[15]. After a membrane capacitance charging time (t > 10−7 
to 10−6 s), Um can be described as:
in which θ designates the angle between the direction of the 
normal to the membrane at the considered point on the cell 
surface and the field direction, E the field intensity, r the 
radius of the cell, g(λ) a function of the specific conductivi-
ties of the membrane (λm), the pulsing buffer (λo) and the 
cytoplasm (λi), the membrane thickness and the cell size 
and f, which is a shape factor (a cell being a spheroid). Um 
is not uniform on the cell surface. These physical predic-
tions were checked experimentally by using potential dif-
ference-sensitive fluorescent probes [16, 17]. A key conclu-
sion is that the induced transmembrane voltage depends on 
the cell size.
When the induced transmembrane voltage exceeds a cer-
tain value Uc (between 0.2 and 1 V), which depends on the 
pulse parameters—number and duration [18]—the part of the 
cell membrane where |Um| > Uc is permeabilized—i.e., elec-
trically conductive defects are formed in the membrane ena-
bling the transport of molecules through the membrane [19].
The molecular reorganization of the membrane associ-
ated with this strong increase in transport is not fully under-
stood, but a long-lived alteration of the membrane solution 
interface was observed [20]. Morphological changes of 
pulsed cells are present as a long-lived swelling is detected 
[21] associated with a global change in the membrane 
rheological properties [22]. No dramatic changes in the 
membrane organization are present in the long term [23]. 
(1)Um = fg()rEcosθ
However, significant but transient cytoplasmic disorganiza-
tion occurs. Microtubules and microfilaments are disorgan-
ized, while intermediate filaments remain intact [24, 25]. 
Indeed, these alterations of the cytoskeleton are transient 
and under strong dependence on the composition of the 
pulsing buffer. The recovery of the cytoskeleton is asso-
ciated with the short life of the permeabilized state of the 
membrane that recovers its selective permeability within a 
few minutes at physiological temperature [26]. This reseal-
ing process is not just due to the viscoelasticity of the 
membrane, but occurs through defect patching mediated by 
exocytotic pathways [27].
The membrane structural alterations induced by the 
electric pulses support transmembrane transport by dif-
fusion of low molecular weight hydrophilic molecules. 
Membrane permeabilization due to electric pulses is non-
selective and molecular flow occurs in both directions. The 
introduction of drugs like bleomycin or cisplatin is facili-
tated with consequent increase in their efficiency [12]. An 
important consequence of increased membrane perme-
ability is also the outflow of secondary metabolites, like 
adenosine and guanosine triphosphate (ATP, GTP), which 
affects cell behavior [28, 29]. This may explain in part the 
observed effects on the cytoskeleton polymerization, which 
is controlled by these small molecules. Leakage of the ATP 
is also a danger signal and associated with immunogenic 
cell death, thus recruiting immune cells. Furthermore, the 
exposure of cells to electric pulses leads to the formation of 
reactive oxygen species (ROS) [30], which remain present 
during the increased membrane permeability.
Electrophoretic contribution during the pulse remains 
negligible in the long-term loading process [31]. Molecular 
transfer of small molecules (<4 kDa) across the permeabi-
lized area of the membrane is mostly driven by the concen-
tration gradient across the membrane described by the Fick 
equation during the resealing process, i.e., after the pulse 
delivery [32] (Fig. 1).
On the contrary, transmembrane translocation of small 
interfering RNA (siRNA) occurs through the plasma mem-
brane of cells during the electric pulse application [33, 
34], which implies that siRNA does not penetrate the cells 
by diffusion as just described for small molecules. The 
amount of uploaded siRNA is therefore under the control 
of the cumulative pulse duration time and the electric field 
strength (Fig. 1).
In the case of plasmids (pDNA), these macromolecules 
interact with the plasma membrane by forming long-lived 
localized aggregates on the electropermeabilized area of 
the cell membrane [35]. This pDNA/membrane interaction 
occurs on the side where they are dragged by the electric 
field-mediated electrophoresis (Fig. 1). Along succes-
sive pulses, pDNAs accumulate in a restricted number of 
aggregates [36] and are translocated across the membrane. 
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Transport within the cytoplasm is another step that happens 
several minutes after the pulse train. This is an active pro-
cess under the control of the cytoplasmic ATP level. pDNA 
can be present in the cytoplasm in a free form that is trans-
ported to the nuclear envelope by molecular motors along 
the microtubules [37] or can be trapped within endocytotic-
like actin-covered vesicles [38, 39]. During the residence 
time of pDNA in the membrane, associated aggregates are 
affected by the previously mentioned ROS generation. ROS 
generation can be prevented by adding antioxidants [40]. In 
summary, the electric pulses induce electrically mediated 
membrane reorganization, which is a localized event on the 
cell surface, and occur only when the local field strength 
is larger than a certain threshold value. Molecules can then 
cross the membrane giving them access to the cell cyto-
plasm. Molecular transport through the membrane can thus 
be controlled by pulse parameters such as amplitude, dura-
tion, shape, and number of pulses.
The processes occurring before, during, and after appli-
cation of electric pulses are schematically presented in the 
Fig. 1. The delivery of small molecules is shown on an 
example of electrochemotherapy (Fig. 1a): Before the appli-
cation of the pulses, the drug is dispersed around the cell; 
during the pulse and along the resealing of the permeabi-
lized cell membrane, the drug molecules diffuse through the 
membrane with increased permeability; after the application 
of the pulses and the membrane resealing, the drug stays 
trapped in the cell where it can exert its cytotoxic effect. 
The delivery of oligonucleotides is shown on an example of 
siRNA electrotransfer (Fig. 1b): Before the application of the 
pulses, the siRNA molecules are dispersed around the cell; 
during the pulse delivery, the siRNA molecules translocate 
Fig. 1  Schematic cartoon showing the processes occurring before, 
during, and after application of electric pulses (yellow stripe) for the 
delivery of molecules of different sizes into the cell. a Delivery of 
small molecules—an example of electrochemotherapy; b delivery of 
oligonucleotides—an example of siRNA electrotransfer; c delivery 
of larger nucleic acids/macromolecules—an example of pDNA gene 
electrotransfer
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through the permeabilized membrane by electrophoresis; 
after the application of the pulses, the membrane reseals and 
uploaded siRNA molecules can silence the target mRNAs. 
The delivery of larger nucleic acids, i.e., macromolecules 
is shown on an example of pDNA electrotransfer (Fig. 1c): 
Before the application of the pulses, the pDNA is dispersed 
around the cell; during the delivery of the pulses, pDNA is 
dragged by the electric field-associated electrophoresis to the 
membrane where it adsorbs to the permeabilized part of the 
membrane and forms localized aggregates; during the reseal-
ing of the membrane, the pDNA is translocated across the 
membrane and transported to the nuclear envelope either by 
cytoskeletal transport or within endocytotic-like vesicles; 
once inside the nucleus, the gene encoded by the pDNA is 
transcribed, and then, therapeutic protein is translated on the 
ribosomes and, in the case of a gene encoding a secretory 
protein (for instance IL-12), the product is secreted by the 
cell; in the case of genes coding for tumor-associated anti-
gens (TAA), proteins will be expressed in their cellular com-
partments (cell membrane or cytoplasm).
Drug and gene delivery to cells in tissue depends 
on additional factors
The behavior of cells when exposed to electric fields 
(pulses) cannot be translated directly from cells in vitro to 
tissues in vivo. Cells in tissue are embedded in a matrix, 
they are of several types in a certain organ (heterogeneous 
population), and they form electrical connections between 
themselves mediated by cell-to-cell junctions [41]. So the 
values of critical electric field at which cell membrane 
becomes permeabilized cannot be determined in vitro and 
then used in in vivo experiments. Furthermore, different 
tissue properties such as perfusion (better perfusion is usu-
ally associated with higher electric conductivity), cell den-
sity and cell volume fraction, preferential orientation like 
in muscle, all affect the electric conductivity of the tissue. 
Skin has a considerably lower conductivity than any other 
tissue; muscle conductivity along muscle fibers is higher 
than in perpendicular direction and tumor tissues gener-
ally have higher conductivity than tissue in which they 
Fig. 2  Electric field distribution in and around the tumor tissue during the application of electric pulses for plate (left) and hexagonal needle 
electrodes—cross section through the mid-plane of the electrodes (right). The electric field distribution is indicated with the rainbow color scale
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are embedded—even in the liver, which is highly conduc-
tive tissue [42]. As a consequence, when we deliver elec-
tric pulses using electrodes (either penetrating needles type 
or nonpenetrating, e.g., surface plate electrodes or pins), 
the electric current distributes according to the electrode 
and tissue geometry and tissue conductivity; current and 
electric field are dual and are connected in place and time 
through Ohm’s law (Fig. 2). In principle at the same cur-
rent, higher conductivity will result in lower electric field 
and vice versa. This means that if electric pulses are applied 
across the skin, the highest electric field will be in the skin 
[43]. As electroporation of cell membrane is a consequence 
of induced transmembrane voltage on the cell membrane 
[15], cells in high electric field will get permeabilized first. 
Once they are permeabilized, the conductivity changes and 
electric field distribution changes as well [44].
It has been shown before that geometry of electrodes and 
tissue electric properties (i.e., conductivity) determines the 
electric field which in turn results in increased cell mem-
brane permeability [45]. This means that we can, by choos-
ing different electrodes and controlling their placement 
with respect to target tissue, achieve controlled membrane 
permeabilization of target tissues [42, 46]. This is true 
and well used in treating deep-seated tumors by means of 
electrochemotherapy [47], but is also true that when using 
different electrodes in the same in vivo “assay,” different 
results are achieved [48] as will be discussed later.
Taking into account the nonhomogeneous nature of tis-
sue [43] and that permeabilization of the cell membrane 
also depends on the duration and number of the applied 
pulses [18], at the current state of knowledge, it is impor-
tant to determine experimentally, which is the threshold 
and necessary electric field to be achieved in target tissue. 
This was determined to be 400 V/cm for 8 short (100 µs) 
duration electric pulses, delivered at 1 Hz pulse repetition 
frequency for the delivery of small molecules to tumors in 
vivo [49]. The course of tissue permeabilization was stud-
ied on a mathematical model of a subcutaneous tumor in 
small animals [49] and seems also to correspond well in 
humans based on clinical observations [50]. For rabbit liver 
using the same parameters, threshold was determined to be 
460 V/cm [51, 52]. For rat muscle, the threshold was dif-
ferent depending on whether the pulses were delivered in 
parallel or perpendicular to the muscle fiber orientation and 
was 80 and 200 V/cm, respectively [53].
Electric field distribution in and around the tumor tis-
sue during the application of electric pulses for the plate 
and hexagonal needle electrodes is shown in the Fig. 2. If 
the electric field is under the threshold for reversible elec-
troporation, the cells are not affected by electroporation 
(Fig. 2, white areas); if the electric field is above the thresh-
old for reversible and under the threshold for irrevers-
ible electroporation, the cells can reseal and survive after 
electroporation (Fig. 2, blue to red areas); and if the electric 
field exceeds the threshold for irreversible electroporation, 
the cells are destroyed/damaged by the effects of irreversi-
ble electroporation, thermal effect, and pH changes (Fig. 2, 
black areas).
For gene electrotransfer in vivo it was shown that mem-
brane permeabilization, which is achieved by high voltage, 
i.e., permeabilizing pulse(s), is a critical step [54]. But per-
haps even more critical is using sufficiently long (from 1 
to several 100 ms) low voltage electric pulse or a combi-
nation of low voltage electric pulses that are applied after 
membrane permeabilization, to achieve effective uptake of 
pDNA into the target cells in tissue [55, 56]. Several differ-
ent combinations of high voltage, short duration and low 
voltage, long duration electric pulses were tested and deter-
mined empirically for successful gene electrotransfer into 
different tissues, muscle, skin, tumor, and liver (for specific 
electrical parameters see [57]). However, several other elec-
trical parameters employing only one type of pulses could 
also be used for effective gene electrotransfer to tumors 
muscle and skin [58–61]. Longer pulses, however, were 
mostly reported to be needed for successful gene transfer.
As the electric field in the tissue depends on tissue 
properties and anatomy (i.e., geometry), it is important 
to define target tissue, which is relatively easy in case of 
tumors and electrochemotherapy, but less in the case of 
gene electrotransfer aiming at achieving immune response 
[62]. Depending on the type of therapeutic gene, i.e., tumor 
antigen or co-stimulatory immune molecules and the tar-
get tissues (skin—only dermis or also subcutaneous tissue, 
muscle, etc.), the target cells in specific tissue are differ-
ent. Furthermore, it was also shown that target cells are not 
necessarily present where and when the pulses are applied 
for the first time [63]. For instance, exposure of skeletal 
muscle to electric pulses alone causes influx of inflamma-
tory cells that can uptake the pDNA injected several days 
after the application of electric pulses [63], thus resulting 
in strong and fast immune response. Furthermore, we need 
to be aware that for gene electrotransfer, it is mandatory 
to achieve reversible permeabilization in cells that need 
to be transfected and avoid irreversible electroporation of 
these same cells, since they should not be damaged as they 
need to express the transgene. Finally, we need to be aware 
that even it might seem rather controversial at the first 
glance, short membrane permeabilizing, i.e., short, high 
voltage electric pulses may be less detrimental to the tis-
sue than electrophoretic, i.e., long, low voltage pulses, as 
they result in higher temperature increase [64], but also in 
large changes of pH, even extreme changes [65]. However, 
these are mostly restricted to the immediate vicinity of the 
electrodes.
Another important aspect that needs to be taken into 
account when evaluating the gene electrotransfer protocols 
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is the usage of plasmids encoding reporter genes. The 
results from the studies using reporter genes cannot be 
directly transferred to the therapeutic application of gene 
electrotransfer. Different efficiency was achieved by the 
same electrodes and treatment parameters considering gene 
expression of reporter gene Luciferase in cells in situ (the 
ones that were exposed to electric pulses) or at induced 
immune response of plasmid encoding modified form of 
human telomerase reverse transcriptase gene (hTERT) 
measured by hTERT-specific cytotoxic T cells (CTL) iso-
lated from spleens 14 days after gene electrotransfer to skin 
[48].
Electrochemotherapy elicits immune response
Electroporation represents a platform technology for deliv-
ery of different molecules to cells and tissues. From its pre-
clinical development, it has quickly been transferred into 
the treatment of tumors in human and veterinary oncology 
[13]. Electroporation leads to a transient increase in the 
permeability of cell membranes when exposed to electric 
pulses [13]. By use of this technology, specific chemo-
therapeutic molecules like bleomycin and cisplatin have 
enhanced uptake in the cells, thus leading to their better 
cytotoxic effectiveness. This therapeutic approach, electro-
chemotherapy, has 50–80 % complete response rate of the 
treated tumors [67], but has only a local effect without sys-
temic effect on distant metastases.
Electrochemotherapy induces apoptotic and necrotic cell 
death in tumors, and extensive necrotic areas in the tumors 
are observed after a few days [68]. This leads to tumor anti-
gen shedding in the tumor surrounding. Several lines of 
evidence support this notion. Recently, properties of immu-
nogenic cell death after electrochemotherapy were demon-
strated in a murine tumor model [66].
Firstly, some of the preclinical studies demonstrated 
infiltration of immune cells into the tumors, indicating an 
inflammatory reaction [69]. This reaction is due also to the 
liberation of the cell metabolites that are shed from cells 
that underwent necrotic cell death, and elicits adaptive 
immune response [66]. Besides preclinical studies [51], 
also electrochemotherapy of human melanoma induced 
maturation of dendritic cells (DC) and their subsequent 
migration into draining lymph nodes [70]. Furthermore, 
the release of ATP after electroporation of cells serves also 
as attractant for DC and their precursors and favors their 
maturation into antigen presenting cells [66].
Secondly, for complete regression of the tumors after 
electrochemotherapy, we need to eradicate (kill) all the 
tumor-initiating (stem) cells. However, due to the techni-
cal limits, as well as tissue properties, we cannot effec-
tively cover whole tumor with the sufficient electric field 
to permeabilize all cells within the tumor, or the drug is not 
available for the cells’ uptake. Thus, we have to presume 
that the immune response is responsible for the eradica-
tion of all the remaining tumor cells, which is supported by 
the results of the study where we demonstrated that after 
electrochemotherapy complete responses of the tumors 
were obtained in immunocompetent mice, whereas in T 
cell-deficient nude mice not [51, 71, 72]. Such observations 
are common also after radiotherapy [73]. Another line of 
evidence comes from the studies where adjuvant treatment 
using different cytokines, like IL-2 and TNF-α, were com-
bined with electrochemotherapy resulting in increased anti-
tumor effectiveness [69, 71, 74].
Thirdly, one of the first studies of electrochemotherapy 
in immunocompetent mice has indicated on the induction 
of the systemic immune response after electrochemother-
apy of tumors. Monocytes isolated from venous blood of 
electrochemotherapy-treated mice showed increased abil-
ity to elicit oxidative burst by production of toxic oxygen 
species 7 days after treatment. Besides activation of mono-
cytes, which are involved in nonspecific tumor destruction 
and activation of other components of the immune system, 
also adaptive immune arm was activated, demonstrated by 
activation of T lymphocytes. However, this activation may 
not be sufficient for abscopal effect on distant metastases 
[75]. On the other hand, none of the in vitro and in vivo 
studies in mice or clinical studies have demonstrated that 
electrochemotherapy promotes metastatic process in the 
organism [75–77]. However, it was shown that electro-
chemotherapy can induce immunogenic cell death demon-
strated by exposure of calreticulin, liberation of ATP, and 
the release of high mobility group box 1 protein from CT26 
colon carcinoma cells in vitro. Such electrochemotherapy-
treated cells, when injected into syngeneic mice also pro-
tected the animals against tumor challenge demonstrating 
vaccination effect [66]. Hence, electrochemotherapy may 
represent an interesting approach to treat solid tumors 
while preventing recurrence and metastases.
Fourthly, the effect of electrochemotherapy depends also 
on the immunogenicity of the treated tumors; more immu-
nogenic tumors respond better and with a higher cure rate 
[78, 79]. In line with these observations, we can also specu-
late that although electroporation is an effective technol-
ogy for drug delivery, based mainly on physico-electrical 
properties, the response rate of the tumors at least to some 
degree depends also on the tumor type, having in mind also 
intrinsic sensitivity (resistance) to the chemotherapeutic 
drug [69, 79, 80]. Some lines of evidence for that exist also 
for human studies since slight variations in tumor respon-
siveness were observed in meta-analysis performed on clin-
ical studies on electrochemotherapy published so far [67]. 
Furthermore, a clinical study on electrochemotherapy of 
melanoma in patients has demonstrated tumor-infiltrating 
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lymphocytes following treatment, but there was no corre-
lation between their number or distribution and the local 
response or visceral spread, whereas FoxP3 as a master 
control gene of Treg was upregulated in tumors that had 
faster dissemination into the visceral organs [91].
Electrotransfer of immunomodulatory genes adds 
a systemic component to electrochemotherapy
Gene electrotransfer is another electroporation-based appli-
cation, where pDNA or siRNA molecules can be delivered 
to various tissues, including tumors [81, 82].
Gene electrotransfer is considered to be an effective tool 
in eliciting antigen-specific immune response in small and 
large animal models, being responsible for the generation 
of an inflammatory environment with immune cell infiltra-
tion [83]. The migration of these cells seems to be essential 
to initiate an adequate immune response to the DNA vac-
cine, proving that this technique is effective in the stimula-
tion of humoral and cellular immunity [84].
Depending on the immunogenicity of the tumors and the 
immune status of the organism, in vivo gene electrotransfer 
of pDNAs coding for immunomodulatory molecules such 
as cytokines, chemokines, adjuvant sequences, siRNA, and/
or administration of DNA vaccines carrying tumor-specific 
or TAA can be used alone or in combination with chemo-
therapeutics for treatment of tumors [85]. Several therapeu-
tic genes were examined, IL-12, VEGF, PDGF-α, etc. [86–
88], but no detailed study of the immune response locally 
or systemically was conducted. All these studies report that 
gene electrotransfer is effective in activating the antitumor 
effectiveness. The therapeutic gene can be administered 
either intratumorally or peritumorally for predominantly 
local effectiveness, or into the muscle to induce systemic 
shedding of the therapeutic molecule. Some studies using 
Fig. 3  Proposed model for electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. ECT electrochemo-
therapy, GET gene electrotransfer
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IL-2 or IL-12 demonstrated also the antitumor effective-
ness on distant untreated tumors and long-term memory of 
the immune system to tumor cells [69, 89, 90]. As a sin-
gle treatment, the intratumoral administration of cytokine 
gene electrotransfer seems the most appropriate way to 
obtain good therapeutic effect. One of the most studied 
cytokines is IL-12, with several preclinical studies in differ-
ent tumor types demonstrating its effectiveness [87], which 
was proved also in clinical treatment of melanoma patients 
[86]. Daud et al. [11] have demonstrated that treatment of 
a few melanoma nodules in the patient can elicit, in cer-
tain patients, slow, but an efficient immune response of the 
organism that results in regression of the treated and also 
nontreated nodules, as well as prolonged survival without 
progression of the disease.
Some studies have also explored the combination of 
local therapies with the gene electrotransfer of immu-
nomodulatory genes. The combinations with either radio-
therapy or electrochemotherapy were explored. The strat-
egy was similar, radiosensitization or chemosensitization 
by immunoadjuvant therapy that boosted the immune 
response of the organism against tumor [77, 91–96]. A 
good potentiation of the radiation response and electro-
chemotherapy was noted, but the underlying immunomod-
ulatory mechanisms were not explored. The knowledge of 
the mechanisms underlying the elicited immune response 
by local therapy, such as electrochemotherapy, would lead 
into the proper scheduling of suitable combination thera-
pies for elicitation of systemic immune response. Thus, 
appropriate dosage of the pDNA encoding immunomodu-
latory molecules and the scheduling of it need to be deter-
mined [97]. Additionally, suitable biomarkers that would 
predict the treatment response are needed. Currently, it 
seems that several consecutive immunogene therapies are 
necessary. Indeed, in preclinical studies, it was shown that 
at least three consecutive immunogene electrotransfers 
should be performed, one prior to electrochemotherapy 
and two consecutive ones thereafter [78]. Skin gene elec-
trotransfer is very appealing, since the skin is a tissue with 
vast amounts of immune cells capable of eliciting an effi-
cient vaccination and boosting effect. Some studies have 
already shown that DC activation in the treatment of mela-
noma may be an exciting approach [98] (Fig. 3).
The immune response linked to electrochemotherapy 
and immunomodulatory gene electrotransfer remains to 
be fully investigated taking into account also the inhibi-
tory function of Tregs, which have been implicated as 
one of the major suppressive mechanisms of antitumor 
immune responses. In the tumor environment, Treg-
induced immune suppression poses a significant barrier to 
anticancer responses targeted by immunotherapeutic strate-
gies. Whelan et al. [4] have demonstrated that an increase 
or decrease in Tregs has a direct influence on the effect of 
an immunotherapy approach administered by gene electro-
transfer of plasmid vectors encoding GM-CSF and B7-1, 
coupled with the systemic administration of Treg inactiva-
tion molecules such as anti-CD25 antibody. More recently, 
the new results indicate the potential for combining Treg 
depletion with immunotherapy-based gene electrotransfer 
into the B16F10 melanoma tumor model to decrease sys-
temic metastasis and potentially enhance survival [99].
Current data also support the idea that it is possible 
to induce elimination or inhibition of immunosuppres-
sive Treg cells through chemotherapy [100]. Thus, such 
approach should be especially focused on the possibility 
to strengthen anticancer immune reactivity. New targeted 
chemotherapy should therefore be used, preferably for the 
induction of immunogenic cancer cell death [3].
Here, we propose a model, a combination of electro-
chemotherapy with immunostimulating peritumoral IL-12 
electrotransfer, as a proof of principle that electrochemo-
therapy can be used as in situ vaccination boosted with 
immunogene electrotransfer (Fig. 3). In the untreated 
tumor (Fig. 3, left), immunosuppressive microenviron-
ment with suppressive immune cells like Tregs and mye-
loid-derived suppressor cells (MDSC) leads to tumor 
tolerance, and tumor cells escape the immune system 
and can replicate uncontrollably and spread through the 
body to form distant secondary tumors. The electrochem-
otherapy-induced vaccination boosted with IL-12 immu-
nogene therapy (Fig. 3, right) leads to the breaking of 
the tolerance to otherwise weekly immunogenic intrin-
sic tumor antigens that result in an antitumor immune 
response and memory responsible for regression of the 
treated tumor and untreated distant metastases. Namely, 
electrochemotherapy-induced tumor cell deaths (Fig. 3, 
speech balloon 1) combined with IL-12 released into the 
bloodstream from the transfected cells in the peritumoral 
region (Fig. 3, speech balloon 2) create a pro-inflamma-
tory microenvironment that leads to recruitment of cir-
culating immune cells. Tumor cells die, at least in part, 
by immunogenic form of cell death characterized by the 
shedding of TAA and danger-associated molecular pat-
tern molecules (DAMP) (Fig. 3, speech balloon 3) from 
the dying cells. Released TAA are captured by DC (Fig. 3, 
speech balloon 4) that migrate to local lymph node-like 
structures called tertiary lymphoid structures (TLS) [101] 
or to the draining lymph nodes (Fig. 3, speech balloon 5) 
where they initiate adaptive antitumor immune response 
by priming the naïve T cell to become effector and mem-
ory T cells. Tumor-specific lymphocytes, like cytotoxic 
T lymphocytes and Th1 cells, are then released from the 
lymphoid structures via circulation and can infiltrate the 
primary tumor site (Fig. 3, speech balloon 6) and distant 
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metastases (Fig. 3, speech balloon 7) where they exert 
their immunological actions.
Furthermore, an exciting therapeutic approach to further 
provide a systemic effectiveness and to enhance the local 
antitumor response of electrochemotherapy could be the 
immune checkpoint blockade and/or inhibiting Tregs.
Conclusion
Membrane electroporation leading to increased membrane 
permeability is a phenomenon which allows the introduc-
tion of non- or poorly permeant molecules into the cells. 
The key factors governing electroporation are the ampli-
tude of induced transmembrane voltage which depends on 
the electric field to which the cell is locally exposed, to the 
cell size, shape, and its orientation in the field. It is impor-
tant to stress that the local electric field E is the critical 
parameter for membrane electroporation/permeabilization 
as it defines the area of the membrane which is permea-
bilized and through which ionic and molecular transport 
occurs [102].
Similar to the effects at the molecular and cellular level, 
a considerable amount of knowledge has been accumulated 
about properties of tissues and how these affect cell elec-
troporation in the tissue and consequently drug and gene 
electrotransfer. In spite of the fact that the exact mecha-
nisms involved at the molecular level of the cells and tis-
sue electroporation are not fully understood, it is possible 
to determine a set of electrical parameters, providing safe 
and efficient procedure for in vivo applications that could 
be translated into clinical use.
Electrochemotherapy is an efficient local ablative treat-
ment, which is currently employed in numerous oncology 
centers throughout Europe. However, it is a local treatment, 
which would need a systemic component that would boost 
the immune response of electrochemotherapy itself. There-
fore, gene electrotransfer of immunomodulatory molecules 
in the peritumoral skin could add this systemic compo-
nent, by enhancing locoregional and/or systemic response. 
Hence, we propose a strategy, where electrochemotherapy-
treated tumor could be used as a live vaccine in conjunction 
with gene electrotransfer to tumors.
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